Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
E. Leich, Marianne Brodtkorb, T. Schmidt, M. Altenbuchinger, Ole Christian Lingjærde, S. Lockmer, H. Holte, T. Nedeva, T. Grieb, B. Sander, C. Sundström, R. Spang, E. Kimby & A. Rosenwald. (2023) Gene expression and copy number profiling of follicular lymphoma biopsies from patients treated with first-line rituximab without chemotherapy. Leukemia & Lymphoma 0:0, pages 1-11.
Read now
Read now
Cecilie E Kiserud, Sandra Lockmer, Idun Baerug, Alv A Dahl, Eva Kimby & Bjørn Østenstad. (2023) Health-related quality of life and chronic fatigue in long-term survivors of indolent lymphoma – a comparison with normative data. Leukemia & Lymphoma 64:2, pages 349-355.
Read now
Read now
Thomas A Ollila & Adam J Olszewski. (2021) Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma. Cancer Management and Research 13, pages 3935-3952.
Read now
Read now
Felipe Samaniego, Peter McLaughlin, Sattva S. Neelapu, Lei Feng, Michelle Fanale, Loretta Nastoupil, Maria Alma Rodriguez, Barbara Pro, Erin Taylor, Fredrick B. Hagemeister & Nathan Fowler. (2021) Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Leukemia & Lymphoma 62:1, pages 58-67.
Read now
Read now
Elena García-Martínez, Melody Smith, Aitziber Buqué, Fernando Aranda, Francisco Ayala de la Peña, Alejandra Ivars, Manuel Sanchez Cánovas, Ma Angeles Vicente Conesa, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2018) Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. OncoImmunology 7:6.
Read now
Read now
Erika Vacchelli, Fernando Aranda, Norma Bloy, Aitziber Buqué, Isabelle Cremer, Alexander Eggermont, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2016) Trial Watch—Immunostimulation with cytokines in cancer therapy. OncoImmunology 5:2.
Read now
Read now
Articles from other publishers (17)
Jesse G. Dixon, Çağlar Çağlayan, Dai Chihara, Tina Nielsen, Natalie Dimier, Jamie Zheng, Anna K. Wall, Gilles Salles, Franck Morschhauser, Robert Marcus, Michael Herold, Eva Kimby, Kristie A. Blum, Michele Ghielmini, Qian Shi & Christopher R. Flowers. (2022) Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials. Clinical Lymphoma Myeloma and Leukemia 22:11, pages e1009-e1018.
Crossref
Crossref
Lisa Blixt, Gordana Bogdanovic, Marcus Buggert, Yu Gao, Sophia Hober, Katie Healy, Hemming Johansson, Christian Kjellander, Sara Mravinacova, Sandra Muschiol, Peter Nilsson, Marzia Palma, Elisa Pin, C. I. Edvard Smith, Olga Stromberg, Margaret Sällberg Chen, Rula Zain, Lotta Hansson & Anders Österborg. (2021) Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients. Leukemia 36:2, pages 476-481.
Crossref
Crossref
Carla CasuloJesse G. DixonFang-Shu Ou, Eva Hoster, Bruce A. PetersonHoward S. Hochster, Pauline BriceMarco LadettoWolfgang HiddemannRobert MarcusEva KimbyMichael HeroldTina NielsenFranck Morschhauser, Mathias RummelAnton HagenbeekUmberto Vitolo, Gilles A. Salles, Qian ShiChristopher R. Flowers. (2021) Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. Blood Advances 5:6, pages 1737-1745.
Crossref
Crossref
Stephen A. Beers & Björn Frendéus. 2021. Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives. Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives
195
225
.
Alden A. Moccia, Christian TavernaSämi Schär, Anna Vanazzi, Stéphanie RondeauFelicitas HitzWalter Mingrone, Thomas Pabst, Lidija CevreskaAuro del Giglio, Johann Raats, Daniel RauchDaniel A. Vorobiof, Andreas Lohri, Céline RuegseggerChristine Biaggi RudolfCorinne RusterholzStefanie Hayoz, Michele GhielminiEmanuele Zucca. (2020) Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. Blood Advances 4:23, pages 5951-5957.
Crossref
Crossref
Eva Kimby, Sandra Lockmer, Harald Holte, Hans Hagberg, Björn E. Wahlin, Peter Brown & Bjørn Østenstad. (2020) The simplified follicular lymphoma PRIMA‐prognostic index is useful in patients with first‐line chemo‐free rituximab‐based therapy. British Journal of Haematology 191:5, pages 738-747.
Crossref
Crossref
Henna-Riikka Junlén, Sandra Lockmer, Eva Kimby & Björn Engelbrekt Wahlin. (2020) Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy. Annals of Hematology 99:10, pages 2357-2366.
Crossref
Crossref
Sandra Lockmer, Weicheng Ren, Marianne Brodtkorb, Bjørn Østenstad, Björn E. Wahlin, Qiang Pan‐Hammarström & Eva Kimby. (2019) M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy. British Journal of Haematology 188:2, pages 259-267.
Crossref
Crossref
Emanuele Zucca, Stephanie RondeauAnna VanazziBjørn ØstenstadUlrich J. M. MeyDaniel RauchBjörn E. WahlinFelicitas Hitz, Micaela HernbergAnn-Sofie JohanssonPeter de Nully Brown, Hans HagbergAndrés J. M. Ferreri, Andreas LohriUrban Novak, Thilo Zander, Hanne BersvendsenMario BargetziWalter Mingrone, Fatime Krasniqi, Stefan Dirnhofer, Stefanie Hayoz, Hanne HawleSimona Berardi Vilei, Michele GhielminiEva Kimby. (2019) Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood 134:4, pages 353-362.
Crossref
Crossref
Sandra LockmerBjørn ØstenstadHans HagbergHarald HolteBjörn Engelbrekt WahlinKarin Fahl WaderKarin Ekström SmedbyPeter BrownEva Kimby. (2019) Reply to M. Sorigue et al. Journal of Clinical Oncology 37:9, pages 759-760.
Crossref
Crossref
Liam Smyth, Rena Buckstein, Nancy Pennell, Rashmi Weerasinghe, Matthew C. Cheung, Kevin Imrie, David Spaner, Eugenia Piliotis, Lisa Chodirker, Marciano Reis, Zeina Ghorab, Liying Zhang, Violet Boudreau, Angela Miliken & Neil Berinstein. (2019) Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-α induces prolonged clinical and molecular remissions in patients with follicular lymphoma. British Journal of Haematology 184:3, pages 469-472.
Crossref
Crossref
Sandra LockmerBjørn ØstenstadHans HagbergHarald HolteAnn-Sofie JohanssonBjörn Engelbrekt WahlinKarin Fahl WaderChloé Beate SteenPeter MeyerMartin MaisenhølderKarin Ekström SmedbyPeter BrownEva Kimby. (2018) Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up. Journal of Clinical Oncology 36:33, pages 3315-3323.
Crossref
Crossref
R. Karmali, E. Kimby, M. Ghielmini, I.W. Flinn, L.I. Gordon & E. Zucca. (2018) Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas. Annals of Oncology 29:2, pages 332-340.
Crossref
Crossref
Gilles Salles, Martin Barrett, Robin Foà, Joerg Maurer, Susan O’Brien, Nancy Valente, Michael Wenger & David G. Maloney. (2017) Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Advances in Therapy 34:10, pages 2232-2273.
Crossref
Crossref
Qian ShiChristopher R. FlowersWolfgang HiddemannRobert MarcusMichael HeroldAnton HagenbeekEva KimbyHoward HochsterUmberto VitoloBruce A. PetersonEmmanuel GyanMichele GhielminiTina NielsenSabine De BedoutTommy FuNancy ValenteNathan H. FowlerEva HosterMarco LadettoFranck MorschhauserEmanuele ZuccaGilles SallesDaniel J. Sargent. (2017) Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. Journal of Clinical Oncology 35:5, pages 552-560.
Crossref
Crossref
Francesca Pavanello, Emanuele Zucca & Michele Ghielmini. (2017) Rituximab: 13 open questions after 20years of clinical use. Cancer Treatment Reviews 53, pages 38-46.
Crossref
Crossref
Tim Ibbotson. (2016) Advances in the Treatment of Non-Hodgkin’s Lymphoma: Exploring New Frontiers. EMJ Hematology, pages 38-46.
Crossref
Crossref